Kristine Swiderek

Chief Scientific Officer at Mozart Therapeutics

Kristine Swiderek is Chief Scientific Officer at Mozart Therapeutics. She has more than 25 years of research and leadership experience in the biopharmaceutical industry and a proven track record of discovering and developing a wide variety of protein therapeutics. Prior to Mozart, Dr. Swiderek was Senior VP of Research at Alpine Immune Sciences, where she was instrumental in building a pipeline advancing protein-based immunotherapies for treatment of autoimmune disease and cancer. As Chief Scientific Officer at OncoResponse and Theraclone, she developed and executed research and development strategies. She formed multiple R&D partnerships, advanced several therapeutic candidates into the clinic and was instrumental in the spin-out of OncoResponse. She has also held several positions of increasing responsibility at ZymoGenetics, a publicly-listed company where she advanced over a dozen candidates into clinical development. Dr. Swiderek received her Ph.D. in Protein Biochemistry from the Ruhr-Universität in Bochum, Germany. She completed her postdoctoral studies at City of Hope, Duarte, CA and at Indiana University, Indianapolis, IN. She is the author of over 60 peer-reviewed articles and manuscripts.

Timeline

  • Chief Scientific Officer

    Current role